Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where H. F. J. Savelkoul is active.

Publication


Featured researches published by H. F. J. Savelkoul.


Journal of Experimental Medicine | 2002

In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines

Franck J. Barrat; Daniel J. Cua; Andre Boonstra; David F. Richards; Chad Crain; H. F. J. Savelkoul; René de Waal-Malefyt; Robert L. Coffman; Catherine Hawrylowicz; Anne O'Garra

We show that a combination of the immunosuppressive drugs, vitamin D3 and Dexamethasone, induced human and mouse naive CD4+ T cells to differentiate in vitro into regulatory T cells. In contrast to the previously described in vitro derived CD4+ T cells, these cells produced only interleukin (IL)-10, but no IL-5 and interferon (IFN)-γ, and furthermore retained strong proliferative capacity. The development of these IL-10–producing cells was enhanced by neutralization of the T helper type 1 (Th1)- and Th2–inducing cytokines IL-4, IL-12, and IFN-γ. These immunosuppressive drugs also induced the development of IL-10–producing T cells in the absence of antigen-presenting cells, with IL-10 acting as a positive autocrine factor for these T cells. Furthermore, nuclear factor (NF)-κB and activator protein (AP)-1 activities were inhibited in the IL-10–producing cells described here as well as key transcription factors involved in Th1 and Th2 subset differentiation. The regulatory function of these in vitro generated IL-10–producing T cells was demonstrated by their ability to prevent central nervous system inflammation, when targeted to the site of inflammation, and this function was shown to be IL-10 dependent. Generating homogeneous populations of IL-10–producing T cells in vitro will thus facilitate the use of regulatory T cells in immunotherapy.


Journal of Immunology | 2001

1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.

Andre Boonstra; Franck J. Barrat; Chad Crain; V.L. Heath; H. F. J. Savelkoul; Anne O'Garra

1α,25-Dihydroxyvitamin D3 (vitD3) is an immunoregulatory hormone with beneficial effects on Th1 mediated autoimmune diseases. Although the inhibitory effects of vitD3 on macrophages and dendritic cells are well documented, any direct effects of vitD3 on Th cell development are not clearly defined. Using CD4+Mel14+ T cells derived from mice on a BALB/c and a C57BL/6 genetic background we examined the effect of vitD3 on Th cell development. We demonstrated that vitD3 affects Th cell polarization by inhibiting Th1 (IFN-γ production) and augmenting Th2 cell development (IL-4, IL-5, and IL-10 production). These effects were observed in cultures driven with splenic APC and Ag, as well as with anti-CD3 and anti-CD28 alone, indicating that CD4+ cells can also be direct targets for vitD3. The enhanced Th2 development by vitD3 was found in both BALB/c and C57BL/6 mice. An increased expression of the Th2-specific transcription factors GATA-3 and c-maf correlated with the increased production of Th2 cytokines after vitD3 treatment. The vitD3-induced effects were largely mediated via IL-4, because neutralization of IL-4 almost completely abrogated the augmented Th2 cell development after vitD3 treatment. These findings suggest that vitD3 acts directly on Th cells and can, in the absence of APC, enhance the development of a Th2 phenotype and augment the expression of the transcription factors c-maf and GATA-3. Our findings suggest that the beneficial effects of vitD3 in autoimmune diseases and transplantation operate through prevention of strong Th1 responses via the action on the APC, while simultaneously directly acting on the T cell to enhance Th2 cell development.


Clinical & Experimental Allergy | 2001

Selective development of a strong Th2 cytokine profile in high‐risk children who develop atopy: risk factors and regulatory role of IFN‐γ, IL‐4 and IL‐10

V H J van der Velden; M. P. Laan; M. R. M. Baert; R. De Waal Malefyt; H. J. Neijens; H. F. J. Savelkoul

Background The immunological processes in early life and their relation to allergic sensitization leading to a Th2 cytokine profile are still not well understood.


European Journal of Pharmacology: Environmental Toxicology and Pharmacology | 1995

Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice

E.M. Hessel; Antoon J.M. Van Oosterhout; Claudia L. Hofstra; Joris J. De Bie; Johan Garssen; Henk van Loveren; A. Verheyen; H. F. J. Savelkoul; Frans P. Nijkamp

To investigate the mechanisms underlying airway hyperresponsiveness a murine model was developed with several important characteristics of human allergic asthma. Mice were intraperitoneally sensitized with ovalbumin and after 4 weeks challenge via an ovalbumin aerosol. After aerosol, lung function was evaluated with a non-invasive forced oscillation technique. The amount of mucosal exudation into the airway lumen and the presence of mast cell degranulation was determined. Tracheal responsiveness was measured at several time points after challenge. At these time points also bronchoalveolar lavage and histology were performed. Sensitization induced high antigen-specific IgE levels in serum. Inhalation of ovalbumin in sensitized mice induced an immediate but no late bronchoconstrictive response. During this immediate phase, respiratory resistance was increased (54%). Within the first hour after ovalbumin inhalation increased mucosal exudation and mast cell degranulation were observed. At 12 and 24 h after ovalbumin challenge, mice showed tracheal hyperresponsiveness (29% and 34%, respectively). However, no apparent inflammation was found in the lungs or bronchoalveolar lavage. From these results it can be concluded that hyperresponsiveness can develop via mechanisms independent of an inflammatory infiltrate. Since mast cell degranulation occurred after ovalbumin exposure, we hypothesize that mast cells are involved in the induction of airway hyperresponsiveness in this model.


Clinical & Experimental Allergy | 2000

Markers for early sensitization and inflammation in relation to clinical manifestations of atopic disease up to 2 years of age in 133 high‐risk children

M. P. Laan; M. R. M. Baert; A. M. H. Bijl; A. E. C. M. Vredendaal; F. B. De Waard-Van Der Spek; Arnold P. Oranje; H. F. J. Savelkoul; H. J. Neijens

The combination of genetic susceptibility and environmental factors induce allergic sensitization and subsequently local inflammation, resulting in atopic manifestations.


Human Immunology | 2001

Inhibition of diabetes in NOD mice by human pregnancy factor

Nisar Ahmed Khan; Afshan Khan; H. F. J. Savelkoul; Robbert Benner

Clinical symptoms of Th1 mediated autoimmune diseases regress in many patients during pregnancy. A prominent feature of pregnancy is the presence of human chorionic gonadotrophin hormone (hCG) in blood and urine. In this report we tested the effect of clinical grade hCG (c-hCG) on the development of diabetes, a Th1 mediated autoimmune disease, in nonobese diabetic (NOD) mice. We show that treatment of NOD mice with c-hCG before the onset of clinical symptoms lowered the increased blood glucose levels, reversed the established inflammatory infiltrate of pancreatic tissue, and profoundly inhibited the development of diabetes for prolonged time. c-hCG also induced profound inhibition of the functional activity (i.e. production of IFN-gamma) of Th1 cells. Transfer of spleen cells from c-hCG-treated NOD mice into immunocompromised NOD.SCID mice inhibited the development of diabetes in these otherwise nontreated mice. This shows that the treatment of the donor NOD mice induced persistent changes in the immune system. The antidiabetic activity of c-hCG was not caused by heterodimeric hCG or its subunits. Instead, this antidiabetic activity resided in a fraction of c-hCG preparation that contains a 400-2000 Dalton natural (immuno) modulatory pregnancy factor (NMPF).


Human Immunology | 2002

Inhibition of septic shock in mice by an oligopeptide from the β-chain of human chorionic gonadotrophin hormone

Nisar Ahmed Khan; Afshan Khan; H. F. J. Savelkoul; Robbert Benner

Human chorionic gonadotrophin (hCG) is a heterodimeric placental glycoprotein hormone required in pregnancy. In human pregnancy urine and in commercial hCG preparations (c-hCG) it occurs in a variety of forms, including breakdown products. Several reports have suggested modulation of the immune system by intact hormone, but such effects of breakdown products have not been reported. In a related article (Hum Immunol 62:1315, 2001), it is reported that a 400-2000 Dalton (Da) fraction from c-hCG and from human pregnancy urine inhibits Th1-mediated diabetes in NOD mice. The active component(s) were called natural (immuno)modulatory pregnancy factor(s) (NMPF). This study reports that a single treatment with the same low molecular weight NMPF fraction up to 24-h after high dose lipopolysaccharide (LPS) injection inhibited septic shock in mice. This counteracting effect of NMPF paralleled the downregulation of the effects of LPS on the production of macrophage migration inhibitory factor (MIF) by spleen cells, on the plasma level of liver aminotransferase, and on the expression of several splenic lymphocyte and macrophage surface markers. Based on the primary structure of the beta-chain of hCG a synthetic hexapeptide Valine-Leucin-Proline-Alanine-Leucine-Proline (VLPALP) was designed, which demonstrated it to have the same protective effects as the 400-2000 Da NMPF fraction. These results indicate a new strategy for the treatment of septic shock and the potential of therapeutic use of this synthetic oligopeptide.


Immunology Today | 1994

Cytokine antagonists and their potential therapeutic use

Reno Debets; H. F. J. Savelkoul

New and exciting developments in the understanding of the interaction between cytokines and their receptors, and the clinical application of cytokine antagonists, were discussed at a recent meeting. Here, Reno Debets and Huub Savelkoul revisit this progress.


Pediatric Research | 1996

Development of immune functions related to allergic mechanisms in young children

H Koning; Miranda Baert; Arnold P. Oranje; H. F. J. Savelkoul; H. J. Neijens

The newborn immune system differs quantitatively and functionally from that of adults. Development of the immune system has important implications for childhood diseases. The immaturity of the immune system in the first years of life may contribute to failure of tolerance induction and in the development of allergic disease. T cell function is diminished, especially the capacity to produce cytokines; production of interferon (IFN)-γ, and IL-4 is strongly reduced. IFN-γ has been found to be even lower in cord blood of newborns with a family history of atopy. Differences in other cell types(natural killer cells, antigen-presenting cells, and B cells) could also play a role in the development of allergic disease. Current data suggest that irregularities in IgE synthesis, helper T cell subsets (Th1, Th2, CD45RA, and CD45RO), cytokines (IL-4, IFN-γ), and possibly other cell types may play a role in the development of allergy in childhood. Moreover, the role of cell surface molecules, like co-stimulatory molecules(CD28, CD40L), activation markers (CD25), and adhesion molecules(LFA-1/ICAM-1, VLA-4/VCAM-1) is also discussed. These variables are modulated by genetic (relevant loci are identified on chromosome 5q, 11q, and 14) and environmental forces (allergen exposure, viral infections, and smoke). The low sensitivity of current predictive factors for the development of allergic diseases, such as cord blood IgE levels, improves in combination with family history and by measurement of in vitro responses of lymphocytes and skin reactivity to allergens. New therapeutic approaches are being considered on the basis of our current understanding of the immunopathology of allergic disease, for instance cytokine therapy and vaccination with tolerizing doses of allergen or peptides.


Allergy | 1998

Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75 in atopic children.

M. P. Laan; Hedda Koning; M.R.M. Baert; Arnold P. Oranje; W. A. Buurman; H. F. J. Savelkoul; H. J. Neijens

During inflammation, membrane expression of adhesion molecules and tumor necrosis factor (TNF)‐receptors (TNF‐R) are increased, and soluble forms of these molecules are released. This study analyzed plasma levels ofsICAM‐1 and sE‐selectin as well as TNF‐γ, sTNF‐R55, and sTNF‐R75 in nonallergic (NAA) and allergic asthma patients (AA), atopic dermatitis patients (AD), and healthy children (HC) by ELISA. Plasma levels of sICAM‐1. sE‐selectin. and sTNF‐R, but not TNF‐γ, were detectable, but were not significantly different between the patient groups and healthy children. In the AA group, a significant correlation (rs0.78, P=0.008) was found between sICAM‐1 and sE‐selectin levels. Furthermore, a significant correlation was found between sTNF‐R55 and sTNF‐R75 levels in the AA group (rs=0.70, P=0.025) and in the AD group (rs=0.69, P=O.O27). In AD patients, a significant correlation was observed between sE‐selectin and the disease severity, as measured by the SCORAD index (rs=0.73. P=0.038). Our data demonstrate that plasma levels of sICAM‐1. sE‐selectin, TNF‐a, sTNF‐R55, and sTNF‐R75 were not different between atopic and nonatopic children during a stable phase of the disease. In AD patients, levels of sE‐selectin seemed to be related to clinical severity of the disease.

Collaboration


Dive into the H. F. J. Savelkoul's collaboration.

Top Co-Authors

Avatar

Robbert Benner

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

H. J. Neijens

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

G. J. M. Tibbe

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A.C.T.M. Vossen

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Georg Kraal

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. P. Laan

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

M.R.M. Baert

Erasmus University Rotterdam

View shared research outputs
Researchain Logo
Decentralizing Knowledge